Drug intelligence / Profile preview

OTO-203

Development stage: Unknown
Lead developer: Otonomy
Modality: Small Molecules
Administration: Otic

Overview

**OTO-203** was an Otonomy preclinical sustained-release, locally delivered antibiotic/corticosteroid combination product intended to treat otitis media. In 2010, Otonomy described the program as being in IND-enabling or preclinical development, with clinical studies anticipated for 2011. Public contemporaneous sources do not identify the individual active ingredients, dosage form, or molecular targets; OTO-203 should therefore not be conflated with OTO-201, Otonomy's separate sustained-release ciprofloxacin program. ([venturecapitaljournal.com](https://www.venturecapitaljournal.com/otonomy-raises-10-million/))

Beyond the preview

Go deeper on OTO-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTO-203.

Explore the full profile